- Policy
- Vaccination will be given for medical staff and the elderly
- by Lee, Jeong-Hwan Dec 29, 2020 06:09am
- The Democratic Party of Korea, the government, and Cheongwadae have decided to start vaccinating COVID-19 from February of next year. On the 27th, the Party, the government, and Cheongwadae held a party government council at the National Assembly to discuss support measures for COVID-19 damage, measures to secure treatment and isolation fa
- Policy
- What are the major systems of the MOHW, the MFDS, & the KCDA
- by Kim, Jung-Ju Dec 29, 2020 06:08am
- From next year, medical expenses for rare diseases and diseases subject to the exempted calculation will be expanded. In addition, the national infrastructure necessary for rapid introduction and verification of the safety and effectiveness of COVID-19 vaccines and treatments using high-tech new technologies will be expanded. The Ministry
- Policy
- The MFDS announces it will shorten the lot release period
- by Lee, Tak-Sun Dec 29, 2020 06:08am
- The MFDS announced on the 27th that a preliminary review is currently underway for three items of COVID-19 vaccines developed by overseas pharmaceutical companies, and that a domestic antibody treatment development company is planning to apply for use approval within this month. The MFDS said that it would approve the COVID-19 vaccine with a tar
- Policy
- Stop the politicization of COVID-19!
- by Lee, Jeong-Hwan Dec 28, 2020 07:25pm
- Cheongwadae directly refuted criticism from some media and opposition parties that President Moon Jae-in and the government coping with the lack of efforts to secure COVID-19 vaccine supplies. Since last April, President Moon's instructions regarding securing the corona vaccine have been disclosed, and a strong appeal to stop the politica
- Policy
- RSA-renewed Blincyto and PVA Xalkori pricing reduced
- by Kim, Jung-Ju Dec 28, 2020 06:13am
- Amgen Korea’s Blincyto 35 μg (blinatumomab) renewed the risk sharing agreement (RSA) with the National Health Insurance Service (NHIS) prior to its termination. As a result, the pricing was lowered by 11.4 percent, effective from next month. With surging sales, Pfizer Pharmaceutical Korea’s Xalkori (crizotinib) is now categorized as a sub
- Policy
- The MFDS begins preliminary review of Janssen's vaccine
- by Lee, Tak-Sun Dec 28, 2020 06:12am
- Following AstraZeneca and Pfizer, Janssen also applied for a preliminary review to the MFDS for approval. The MFDS announced on the 22nd that Janssen (Johnson & Johnson) has applied for a preliminary review before applying for approval of COVID-19 Vaccine. This vaccine is one of the vaccines that the government has announced plans to i
- Policy
- Government TF to counteract pricing reduction litigations
- by Lee, Hye-Kyung Dec 24, 2020 06:10am
- The South Korean health authority is seeking for measure to keep their drug pricing reduction decision effective. Until recently, the Ministry of Health and Welfare (MOHW), the National Health Insurance Service (NHIS) and the Health Insurance Review and Assessment Service (HIRA) have been operating a taskforce for pricing reduction litigatio
- Policy
- TOC prevents the first approval of COVID-19 vaccine in Korea
- by Lee, Tak-Sun Dec 24, 2020 06:10am
- This is a response from the health authorities to concerns that the COVID-19 vaccine developed by AstraZeneca will be introduced in Korea in February-March next year, although approval by the US FDA is delayed. The MFDS is independently screened regardless of overseas institutions. However, Korea's licensing regulations require approval fr
- Policy
- References related to COVID-19 will not be present
- by Lee, Jeong-Hwan Dec 24, 2020 06:09am
- As the personnel hearing of candidate Kwon Deok-cheol of the MOHW took place in the morning of today (22), the adoption of references such as CEOs of Pfizer and AstraZeneca for inquiries related to COVID-19 vaccine was finally broken due to disagreement between the ruling party and the opposition party of the National Assembly Health and Welf
- Policy
- Korean clinical trial of MSD’s V114 is being conducted
- by Lee, Tak-Sun Dec 23, 2020 06:10am
- MSD's pneumococcal vaccine candidate is conducting phase III clinical trials for infants in Korea. It is noteworthy whether MSD will become a strong competitor in the Korean pneumococcal vaccine market dominated by Pfizer's Prevenar 13. On the 21st, the MFDS approved a phase III clinical trial plan for the pneumococcal vaccine candidate V1
